Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 319 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: vancomycin Clear all
Not yet recruiting Not applicable Interventional

Intraosseous Antibiotics for Osseointegration

NCT07621094
View directory record Official record
Conditions
Osseointegration Infection
Interventions
intraosseous antibiotic delivery
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Aurora, Colorado • New York, New York • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 18, 2026, 2:05 PM EDT
Terminated Phase 1 Interventional

Efficacy and Safety of Umbilical Cord Blood Injection for Critical Limb Ischemia

NCT01019681
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Cord blood stem cell injection
Biological
Lead sponsor
Richard Burt, MD
Other
Eligibility
18 Years to 72 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 18, 2026, 2:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Antibiotic Outbreak, Risk Factors for Never Event, Prediction of Inappropriate Use

NCT03489330
View directory record Official record
Conditions
Infectious Disease
Interventions
Not listed
Lead sponsor
Midwestern University
Other
Eligibility
18 Years to 90 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Downers Grove, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 18, 2026, 2:05 PM EDT
Not yet recruiting Phase 1 Interventional

Fecal MicrobiotaTransplant for the Treatment of Parkinson's Disease

NCT06647277
View directory record Official record
Conditions
Parkinson Disease
Interventions
Fecal Microbiota Transplant
Combination Product
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 18, 2026, 2:05 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

NCT00091819
View directory record Official record
Conditions
Staphylococcal Skin Infection
Interventions
Telavancin, Vancomycin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
National City, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 18, 2026, 2:05 PM EDT
Terminated Phase 2 Interventional Results available

Clinical Trials to Reduce the Risk of Antimicrobial Resistance

NCT01570192
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
IV meropenem, I.V. Meropenem, Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h, Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage., tobramycin nebulization
Drug · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
8
States / cities
San Mateo, California • Gainesville, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2017 · Synced Oct 18, 2026, 2:05 PM EDT
Completed Phase 3 Interventional Results available

Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT01811732
View directory record Official record
Conditions
Skin and Subcutaneous Tissue Bacterial Infections
Interventions
Delafloxacin, Vancomycin, Aztreonam, Placebo
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
17
States / cities
Montgomery, Alabama • Anaheim, California • Chula Vista, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 18, 2026, 2:05 PM EDT
Completed Phase 3 Interventional

Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count

NCT00003805
View directory record Official record
Conditions
Bone Marrow Suppression, Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
piperacillin sodium, piperacillin-tazobactam, tazobactam sodium, vancomycin
Drug
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
2 Years and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2012 · Synced Oct 18, 2026, 2:05 PM EDT
Recruiting Phase 1Phase 2 Interventional

Intestinal Microbiome Transplant in ALS

NCT07017946
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis ALS
Interventions
MTP-101C
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 18, 2026, 2:05 PM EDT
Completed Not applicable Interventional

Effectiveness of Enhanced Terminal Room Disinfection to Prevent Healthcare-associated Infections (HAIs)

NCT01579370
View directory record Official record
Conditions
Multidrug Resistant Organisms, Healthcare Associated Infections
Interventions
Quaternary ammonium, Bleach, Quaternary ammonium and UV-C light, Bleach and UV-C light
Other
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
21,395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
9
States / cities
Burlington, North Carolina • Chapel Hill, North Carolina • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 18, 2026, 2:05 PM EDT
Terminated Phase 4 Interventional Results available

Prospective Evaluation of a Vancomycin Nomogram With a Continuous Infusion of Vancomycin for Surgical ICU Patients

NCT01786161
View directory record Official record
Conditions
MRSA - Methicillin Resistant Staphylococcus Aureus Infection
Interventions
Vancomycin continuous infusion, Vancomycin intermittent dosing interval
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Oct 18, 2026, 2:05 PM EDT
Completed No phase listed Observational

To Evaluate the Impact of MRSA Nasal Screen Implementation.

NCT07748143
View directory record Official record
Conditions
MRSA
Interventions
Duration of therapy, Direct Cost, Pharmacokinectic Monitoring, Hospital stay
Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 18, 2026, 2:05 PM EDT
Terminated Phase 4 Interventional Results available

Comparing Oral Versus Parenteral Antimicrobial Therapy

NCT05977868
View directory record Official record
Conditions
Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection, Pulmonary Infection, Gastrointestinal Infection, Genitourinary Infection
Interventions
Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid, Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 18, 2026, 2:05 PM EDT
Terminated Phase 3 Interventional

Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease

NCT00384527
View directory record Official record
Conditions
Clostridium Infections
Interventions
Nitazoxanide, Vancomycin
Drug
Lead sponsor
Romark Laboratories L.C.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
10
States / cities
Torrance, California • Bay Pines, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 18, 2026, 2:05 PM EDT
Active, not recruiting Phase 2 Interventional

Microbiota Transfer Therapy for Adults With Autism Spectrum Disorder (ASD) Who Have Gastrointestinal Disorders

NCT03408886
View directory record Official record
Conditions
Autism Spectrum Disorder, Gastrointestinal Disorder
Interventions
Vancomycin, MoviPrep, Full Spectrum Microbiota
Drug · Biological
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 60 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 18, 2026, 2:05 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Vancomycin for Primary Sclerosing Cholangitis

NCT03710122
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Vancomycin, Placebo
Drug · Other
Lead sponsor
Elizabeth Carey
Other
Eligibility
18 Years to 76 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Phoenix, Arizona • Tempe, Arizona • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 18, 2026, 2:05 PM EDT
Completed No phase listed Observational

Vancomycin vs. Nitazoxanide to Treat Recurrent C. Difficile Colitis

NCT00304889
View directory record Official record
Conditions
Clostridium Enterocolitis, Pseudomembranous Colitis, Antibiotic-Associated Colitis
Interventions
Not listed
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 18, 2026, 2:05 PM EDT
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin

NCT07221708
View directory record Official record
Conditions
Clostridioides Difficile, Vancomycin Resistance Enterococcus Faecium
Interventions
Vancomycin (POC)
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
65 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2027
U.S. locations
1
States / cities
Glen Burnie, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 18, 2026, 2:05 PM EDT
Terminated Phase 4 Interventional Results available

Aerosolized Antibiotics in the Treatment of Ventilator Associated Pneumonia

NCT02478710
View directory record Official record
Conditions
Pneumonia, Ventilator-Associated
Interventions
Aerosolized Tobramycin or Vancomycin, Aerosolized Placebo
Drug
Lead sponsor
Wright State University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 18, 2026, 2:05 PM EDT
Not listed Phase 3 Interventional

Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI

NCT02901717
View directory record Official record
Conditions
Catheter-related Infections
Interventions
Mino-Lok, Antibiotic lock
Drug
Lead sponsor
Leonard-Meron Biosciences, Inc.
Industry
Eligibility
12 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
19
States / cities
Washington D.C., District of Columbia • Gainesville, Florida • Hines, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 18, 2026, 2:05 PM EDT
Recruiting Phase 2Phase 3 Interventional

Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients

NCT07221370
View directory record Official record
Conditions
Clostridium Difficile Infection, Vancomycin Resistant Enterococci Infection
Interventions
Vancomycin 125mg, Placebo
Drug
Lead sponsor
Riverside University Health System Medical Center
Other
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Moreno Valley, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 18, 2026, 2:05 PM EDT
Terminated Phase 4 Interventional

Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty

NCT01196169
View directory record Official record
Conditions
Staphylococcal Infections, Methicillin-resistant Staphylococcus Aureus
Interventions
Daptomycin, Vancomycin
Drug
Lead sponsor
Mountain Home Research & Education Corporation
Other
Eligibility
18 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Johnson City, Tennessee • Mountain Home, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 18, 2026, 2:05 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT01431339
View directory record Official record
Conditions
Abscess, Wound Infection, Surgical Site Infection, Cellulitis
Interventions
IV Dalbavancin, Vancomycin/Linezolid
Drug
Lead sponsor
Durata Therapeutics Inc., an affiliate of Allergan plc
Industry
Eligibility
18 Years to 85 Years
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
30
States / cities
Montgomery, Alabama • Anaheim, California • Buena Park, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Oct 18, 2026, 2:05 PM EDT
Completed Not applicable Interventional Results available

Prevention of Neurosurgical Wound Infections

NCT00915967
View directory record Official record
Conditions
Surgical Wound Infections
Interventions
Vancomycin, Placebo (Saline Solution)
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 99 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 18, 2026, 2:05 PM EDT